MX2013002960A - Composiciones de anticuerpo y metodos de uso. - Google Patents
Composiciones de anticuerpo y metodos de uso.Info
- Publication number
- MX2013002960A MX2013002960A MX2013002960A MX2013002960A MX2013002960A MX 2013002960 A MX2013002960 A MX 2013002960A MX 2013002960 A MX2013002960 A MX 2013002960A MX 2013002960 A MX2013002960 A MX 2013002960A MX 2013002960 A MX2013002960 A MX 2013002960A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- antibody compositions
- antibodies
- compositions
- antibody
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/088—Varicella-zoster virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/089—Cytomegalovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La invención proporciona composiciones que comprenden anticuerpos anti-gH y anticuerpos anti-Complejo I así como métodos de usos de las mismas.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38772510P | 2010-09-29 | 2010-09-29 | |
US38773510P | 2010-09-29 | 2010-09-29 | |
US201161504056P | 2011-07-01 | 2011-07-01 | |
PCT/US2011/054092 WO2012047732A2 (en) | 2010-09-29 | 2011-09-29 | Antibody compositions and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2013002960A true MX2013002960A (es) | 2013-05-09 |
Family
ID=45890018
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013002960A MX2013002960A (es) | 2010-09-29 | 2011-09-29 | Composiciones de anticuerpo y metodos de uso. |
Country Status (21)
Country | Link |
---|---|
US (2) | US20120082666A1 (es) |
EP (1) | EP2621533A4 (es) |
JP (1) | JP2014501491A (es) |
KR (1) | KR20130112879A (es) |
CN (2) | CN103313727B (es) |
AR (1) | AR083214A1 (es) |
AU (1) | AU2011312425A1 (es) |
BR (1) | BR112013007514A2 (es) |
CA (1) | CA2811087A1 (es) |
CL (1) | CL2013000868A1 (es) |
CO (1) | CO6690799A2 (es) |
CR (1) | CR20130133A (es) |
EA (1) | EA201390467A1 (es) |
EC (1) | ECSP13012536A (es) |
HK (1) | HK1189501A1 (es) |
IL (1) | IL225389A0 (es) |
MA (1) | MA34541B1 (es) |
MX (1) | MX2013002960A (es) |
PE (1) | PE20140195A1 (es) |
SG (1) | SG188657A1 (es) |
WO (1) | WO2012047732A2 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112014024023A2 (pt) * | 2012-03-28 | 2017-07-18 | Genentech Inc | anticorpos idiotípicos anti-hcmv e usos dos mesmos |
WO2014099908A1 (en) * | 2012-12-17 | 2014-06-26 | Genentech, Inc. | Methods for inhibiting viral infection in transplant patients |
MX359794B (es) | 2013-03-15 | 2018-10-10 | Intrinsic Lifesciences Llc | Anticuerpos anti-hepcidina y usos de los mismos. |
MX2015016978A (es) * | 2013-06-10 | 2016-04-25 | Merck Sharp & Dohme | Proteinas de union a antigeno neutralizantes de citomegalovirus. |
NZ756749A (en) | 2013-09-13 | 2022-05-27 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
RU2016107435A (ru) | 2013-09-13 | 2017-10-18 | Дженентек, Инк. | Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты |
WO2016049036A1 (en) * | 2014-09-22 | 2016-03-31 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
GB201607979D0 (en) * | 2016-05-06 | 2016-06-22 | Liverpool School Tropical Medicine | Monomeric proteins and uses thereof |
KR20210084535A (ko) * | 2018-10-25 | 2021-07-07 | 케이엠 바이올로직스 가부시키가이샤 | 개변 CMV gB 단백질 및 이것을 포함하는 CMV 백신 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0683675A4 (en) * | 1993-01-28 | 1997-05-21 | Sandoz Pharmaceuticals Corp | HUMAN MONOCLONAL ANTIBODIES AGAINST CYTOMEGALOVIRUS. |
WO1996006625A1 (en) * | 1994-08-26 | 1996-03-07 | Eli Lilly And Company | Antibody constructs with cdr switched variable regions |
US6875433B2 (en) * | 2002-08-23 | 2005-04-05 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein |
AU2005295595C1 (en) * | 2004-10-15 | 2012-06-21 | Seattle Genetics, Inc. | Anti-CD70 antibody and its use for the treatment and prevention of cancer and immune disorders |
BRPI0614366A2 (pt) * | 2005-08-11 | 2009-10-06 | Arpi Matossian Rogers | peptìdeo, anticorpo ou fragmento de anticorpo, anticorpo ou ligante funcionalmente equivalente, molécula de ácido nucleico, vetor, célula hospedeira, métodos para expressar um peptìdeo, um anticorpo ou fragmento de anticorpo, um anticorpo ou ligante equivalente e para tratar uma doença em um paciente, composição farmacêutica, composição de vacina, métodos de vacinação de um indivìduo contra uma doença ou um distúrbio e de diagnose de um indivìduo para a presença de anticorpos autoimunes, e, arranjo de peptìdeos |
US20080003605A1 (en) * | 2006-05-24 | 2008-01-03 | The University Of Chicago | Microarray analysis of light chain variable gene expression and methods of use |
CA2654563A1 (en) * | 2006-06-07 | 2007-12-21 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
DK2126049T3 (da) * | 2006-12-15 | 2011-07-18 | Ribovax Biotechnologies Sa | Antistoffer mod humant cytomegalovirus (hCMV) |
PE20141433A1 (es) * | 2008-07-16 | 2014-10-19 | Inst Research In Biomedicine | Anticuerpos neutralizantes de citomegalovirus humano |
-
2011
- 2011-09-29 CN CN201180057119.7A patent/CN103313727B/zh not_active Expired - Fee Related
- 2011-09-29 AU AU2011312425A patent/AU2011312425A1/en not_active Abandoned
- 2011-09-29 KR KR1020137007881A patent/KR20130112879A/ko not_active Application Discontinuation
- 2011-09-29 CA CA2811087A patent/CA2811087A1/en not_active Abandoned
- 2011-09-29 EA EA201390467A patent/EA201390467A1/ru unknown
- 2011-09-29 EP EP11831352.7A patent/EP2621533A4/en not_active Withdrawn
- 2011-09-29 WO PCT/US2011/054092 patent/WO2012047732A2/en active Application Filing
- 2011-09-29 PE PE2013000655A patent/PE20140195A1/es not_active Application Discontinuation
- 2011-09-29 US US13/248,998 patent/US20120082666A1/en not_active Abandoned
- 2011-09-29 CN CN201510363420.0A patent/CN104945505A/zh active Pending
- 2011-09-29 SG SG2013022751A patent/SG188657A1/en unknown
- 2011-09-29 AR ARP110103598A patent/AR083214A1/es not_active Application Discontinuation
- 2011-09-29 MA MA35760A patent/MA34541B1/fr unknown
- 2011-09-29 BR BR112013007514A patent/BR112013007514A2/pt not_active IP Right Cessation
- 2011-09-29 JP JP2013531893A patent/JP2014501491A/ja active Pending
- 2011-09-29 MX MX2013002960A patent/MX2013002960A/es not_active Application Discontinuation
-
2013
- 2013-03-21 IL IL225389A patent/IL225389A0/en unknown
- 2013-03-21 CR CR20130133A patent/CR20130133A/es unknown
- 2013-03-28 CL CL2013000868A patent/CL2013000868A1/es unknown
- 2013-03-28 EC ECSP13012536 patent/ECSP13012536A/es unknown
- 2013-04-12 CO CO13095273A patent/CO6690799A2/es unknown
-
2014
- 2014-03-17 HK HK14102648.6A patent/HK1189501A1/zh not_active IP Right Cessation
- 2014-12-19 US US14/577,991 patent/US20150376265A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CO6690799A2 (es) | 2013-06-17 |
EP2621533A4 (en) | 2015-06-17 |
PE20140195A1 (es) | 2014-02-24 |
JP2014501491A (ja) | 2014-01-23 |
CL2013000868A1 (es) | 2014-01-24 |
IL225389A0 (en) | 2013-06-27 |
US20150376265A1 (en) | 2015-12-31 |
AR083214A1 (es) | 2013-02-06 |
AU2011312425A1 (en) | 2013-04-11 |
CN103313727A (zh) | 2013-09-18 |
BR112013007514A2 (pt) | 2019-09-24 |
SG188657A1 (en) | 2013-05-31 |
KR20130112879A (ko) | 2013-10-14 |
WO2012047732A2 (en) | 2012-04-12 |
WO2012047732A3 (en) | 2013-05-30 |
CA2811087A1 (en) | 2012-04-12 |
US20120082666A1 (en) | 2012-04-05 |
MA34541B1 (fr) | 2013-09-02 |
CR20130133A (es) | 2013-08-29 |
HK1189501A1 (zh) | 2014-06-13 |
EP2621533A2 (en) | 2013-08-07 |
CN104945505A (zh) | 2015-09-30 |
EA201390467A1 (ru) | 2013-11-29 |
ECSP13012536A (es) | 2013-06-28 |
CN103313727B (zh) | 2015-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013007168A (es) | Anticuerpo anti-pcsk9 y metodos de uso. | |
MX342240B (es) | Anticuerpos anti-fgfr4 y metodos de uso. | |
PH12015502565B1 (en) | Anti-transferrin receptor antibodies and methods of use | |
MX2014004022A (es) | Anticuerpos anti-htra1 y metodos de uso. | |
MX2013002960A (es) | Composiciones de anticuerpo y metodos de uso. | |
PH12014501427B1 (en) | Anti-phf-tau antibodies and their uses | |
PH12015501059A1 (en) | Anti-hemagglutinin antibodies and methods of use | |
MX336001B (es) | Anticuerpos anti-axl y metodos de uso. | |
PH12014502132A1 (en) | Anti-lgr5 antibodies and immunoconjugates | |
MX2014002053A (es) | Anticuerpos anti -mcsp y metodos de uso. | |
MX2013001473A (es) | Anticuerpos contra il-18r1 y usos de los mismos. | |
MX2022000026A (es) | Anticuerpos para tau. | |
MX346500B (es) | Metodos y composiciones para inmunoterapia para enfermedad neural. | |
PH12018500046A1 (en) | Anti-mesothelin antibodies and immunoconjugates | |
JO3118B1 (ar) | تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة | |
MX2013015311A (es) | Polipeptidos de enlace de pcsk9 y metodos de uso. | |
EP2566890A4 (en) | ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE | |
PH12014501605A1 (en) | Anti-lrp5 antibodies and methods of use | |
TN2013000378A1 (en) | Anti - sclerostin antibody crystals and formulations thereof | |
MX2012011829A (es) | Anticuerpos de anti-poliubiquitina y metodos de uso. | |
MX354303B (es) | Anticuerpos de anti-biotina y metodos de uso. | |
AU2011217848A8 (en) | Integrin aVB8 neutralizing antibody | |
MY161868A (en) | Anti-bv8 antibodies and uses thereof | |
MX2014014381A (es) | Anticuerpos de anti-teofilina y metodos de uso. | |
TN2011000041A1 (en) | Compositions and methods for antibodies targeting complement protein c5 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |